Next-generation protease inhibitors, like grazoprevir, glecaprevir, and voxilaprevir, exhibit more favorable safety profiles in patients with compensated cirrhosis, including low (<2%) rates of clinically relevant ALT elevations [7–9]. Here, GPT is linked to Cirrhosis.